Abstract: The present invention relates to an improved process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride of Formula I.
Abstract: The present invention relates to an improved process for the preparation of Escitalopram of the Formula (I), which comprises, isolation of Diol compound as an oxalate salt, resolution of Diol compound and cyclization of resolved compound of Formula (VII). The present invention provides a process to obtain pure Diol compound by preparing its Oxalate salt, which is useful for resolution of enantiomers.
Type:
Grant
Filed:
July 20, 2006
Date of Patent:
May 10, 2011
Assignee:
Aurobindo Pharma Ltd.
Inventors:
Vipin Kumar Kaushik, Umar Khan Mohammed, Sivakumaran Meenakshisunderam
Abstract: The present invention provides a method for the preparation of N-(1-oxopentyl)-N-[[2?-(1H-tetra-zol-5-yl)[1,1?-biphenyl]-4-yl]methyl]-L-valine (Valsartan) which comprises; treating N-[[2?-(1-triphenylmethyl-tetra-zol-5-yl)biphenyl-4-yl]methyl]-L-valine methyl ester (X) with oxalic acid or its hydrates in a solvent to produce N-[[2?-(1-triph-enylmethyl-tetrazol-5-yl)biphenyl-4-yl]methy]-L-valine methyl ester oxalate (Xa) and treating the compound (Xa) with a base in a solvent followed by reacting with valeryl chloride in presence of base in a solvent to produce N-[[2?-(1-triphenylmethyl-tetra-zol-5-yl)[1,1?biphenyl]-4-yl]methyl]-N-valeryl-L-valine methyl ester (XI), de-protecting the compound (XI) using anhydrous acidic conditions to produce N-(1-oxopentyl)-N-[[2?-(1-H-tetrazol-5-yl)[1,1?biphenyl]-4-yl]methyl-L-valine methyl ester (V) followed by treating with base in a solvent to produce Valsartan.
Abstract: The present invention relates to stable aqueous oral formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral formulation of alendronate sodium. The present invention also relates to a process for the preparation of stable aqueous oral formulation of alendronate sodium.
Abstract: The present invention relates to a method for the preparation of Florfenicol from Fluoroamine compound, namely (1R,2S)-1-[4-(methylsulfonyl)phenyl]-2-amino-3-fluoro-1-propanol (II), by reaction with dihaloacetic acid ester in an organic solvent in presence of an inorganic base.
Abstract: An improved process for bisphosphonylation of acids, substituted acids to obtain compounds with the formula using phosphorus trihalide, phosphorus acid, in presence of phenolic compounds as diluent/solvent.
Type:
Grant
Filed:
January 18, 2007
Date of Patent:
May 5, 2009
Assignee:
Aurobindo Pharma Ltd.
Inventors:
Subba Reddy Danda, Narayan K. A. S. S. Garimella, Srinivasa Rao V. N Divvela, Ramesh Dandala, Sivakumaran Meenakshisunderam
Abstract: The present invention relates to an improved process for the selective crystallization of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid sodium in pure hemi-pentahydrate form of Formula (I), by first converting 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid into organic amine salt and then by replacing it with sodium salt.
Type:
Grant
Filed:
January 16, 2007
Date of Patent:
February 3, 2009
Assignee:
Aurobindo Pharma Ltd.
Inventors:
Srinivasa Rao V. N Divvela, Lenin Racha, Sivakumaran Meenakshisunderam, Ramesh Dandala
Abstract: The present invention relates to pharmaceutical compositions of mirtazapine or its pharmaceutically acceptable salts. More particularly, the present invention relates to solid unit dosage forms of anhydrous mirtazapine or its pharmaceutically acceptable salts suitable for oral administration. The present invention also relates to a process for the preparation of pharmaceutical compositions of mirtazapine or its pharmaceutically acceptable salts.
Abstract: The present invention relates to an improved process for the preparation of pure Finasteride of Formula I, which comprises converting dihydrofinasteride to finasteride through novel protected dihydrofinasteride and protected finasteride intermediates.
Abstract: The present invention describes an industrially advantageous process to prepare highly pure 1-Methyl-3-phenylpiperazine of Formula I that makes use of a novel piperazine derivative, 4-Benzyl-1-methyl-2-oxo-3-phenylpiperazine, represented by Formula II 1-Methyl-3-phenylpiperazine is a useful intermediate in the preparation of antidepressant Mirtazapine.
Abstract: This invention relates to a novel process to obtain highly pure 4-(cyclopropylcarbonyl)-?,?-dimethylphenylacetic acid of Formula I through crystallization from a mixture of para and meta regioisomers of Formula I and II in cyclohexane, whereby the amount of undesired meta isomer, 3-(cyclopropylcarbonyl)-?,?-dimethylphenylacetic acid of Formula II is decreased to below 0.5%. The compound of Formula I is a key intermediate for the preparation of high purity terfenadine carboxylate, which is a known antihistaminic.
Abstract: The present invention relates to an industrially advantageous method for the purification of Citalopram (Formula I) wherein desmethyl citalopram (Formula II), present in crude Citalopram as an impurity, is methylated to produce pure Citalopram.